GOSSAMER BIO DEADLINE MONDAY JUNE 1st: Bragar Eagel & Squire, P.C. Urges Gossamer Bio, Inc. (NASDAQ:GOSS) Investors with Large Losses to Contact the Firm Before Monday June 1st

A class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) for allegedly providing materially false and misleading statements regarding its Phase 3 PROSERA study for pulmonary arterial hypertension treatment. The company is accused of expressing confidence in the trial design while concealing adverse facts about placebo response controls at Latin American testing sites, causing investors to purchase securities at artificially inflated prices. Investors who purchased shares between June 16, 2025, and February 20, 2026, have until June 1, 2026, to apply as lead plaintiff.